News

This announcement marks significant progress in the company's debt optimization process, providing a clear signal of capital structure improvement to the market.

This conference will bring together top experts in the field to jointly discuss the latest scientific discoveries related to metabolic dysfunction-associated steatohepatitis (MASH). Meanwhile, the company also disclosed that, in accordance with Nasdaq Listing Rule 5635(c)(4), it has granted an inducement equity award to new employees. Such awards are a common practice among biotechnology companies, aimed at attracting high-quality talent and advancing the company's research and development pipeline.

On one hand, part of the funds will be specifically allocated to pay for the costs associated with Capped Call Transactions signed between the company and counterparties. These types of financial instruments are typically used to reduce the risk of future equity dilution, especially when the company conducts financing activities such as issuing convertible bonds. On the other hand, approximately $66 million of the financing will be used to fully repay its Outstanding Advances under a lease agreement. This move will optimize the company's balance sheet structure and reduce related debt burdens.